Weekly TechBio News

Summary

The episode highlights four major tech‑bio developments: LatchBio’s launch of agent.bio, an interactive sandbox for spatial biology analysis across five platforms; Chai Discovery’s $130 M Series B raise to build an AI‑driven CAD suite for drug design, backed by OpenAI; Accenture Ventures’ investment in Ryght AI, which uses AI Site Twin technology to streamline clinical trial site selection and patient enrollment; and MapLight Therapeutics’ partnership with SandboxAQ to co‑develop AI‑discovered CNS therapies targeting a novel GPCR, with up to $200 M in milestones. These stories illustrate the accelerating integration of AI and digital tools into drug discovery, spatial genomics, and clinical trial operations.